$SPRCMay 28, 2026, 12:40 PMAI processed
NeuroThera (NTLX) gets conditional TSXV approval to buy ~54% of CliniQuantum
AI Summary
NeuroThera Labs, majority-owned by SciSparc (SPRC), received conditional TSX Venture Exchange approval to acquire ~54% of CliniQuantum in exchange for 56.6M NeuroThera shares (≈$9.46M based on 20-day VWAP); the Consideration Shares will be placed in escrow and the SPA was amended to include a $0.05 floor on future earn-out share issuances and lock-ups. CliniQuantum’s main asset is an exclusive license to a single U.S. provisional patent for quantum Monte Carlo simulation methods aimed at improving clinical-trial subgroup identification, and closing remains conditional on obtaining an Israeli tax ruling and final TSXV acceptance (outside date extended to June 1, 2026).
Positives
- TSXV granted conditional approval for NeuroThera to acquire ~54% of CliniQuantum
- Consideration is 56.6M NeuroThera shares (valued ≈ $9.46M on 20-day VWAP) and will be escrowed
- SPA amended to set a $0.05 floor on future earn-out share issuances and includes selling-shareholder lock-ups
Negatives
- Approval is conditional — closing requires an Israeli tax ruling and final TSXV acceptance; outside date extended to June 1, 2026
- Issuance of 56.6M shares represents meaningful dilution risk to NeuroThera/SciSparc shareholders
- CliniQuantum’s principal asset is a license to a single U.S. provisional patent, reflecting early-stage/unproven IP